Overview

Bioavailability of BIBR 953 ZW After Dose of BIBR 1048 MS

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To assess the extent of absorption of 12.5, 50 and 200 mg of BIBR 1048 MS with and without coadministration of 150 mg ranitidine.
Phase:
Phase 1
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Dabigatran
Ranitidine
Ranitidine bismuth citrate